Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Treprostinil in PH-ILD
NCT02630316Phase 3Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Feb 2017
- Primary completion
- Dec 2019
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in pulmonary hypertension (PH) comparing Inhaled Treprostinil with Placebo (2 arms). Primary endpoint: Change in 6-minute Walk Distance Measured at Peak Exposure at 16 weeks. Started Feb 2017; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT02630316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02630316.